Premium
Naringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL‐induced NF‐κB and ERK activation
Author(s) -
Ang Estabelle S.M.,
Yang Xiaohong,
Chen Honghui,
Liu Qian,
Zheng Ming H.,
Xu Jiake
Publication year - 2011
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2011.07.046
Subject(s) - naringin , bone resorption , rankl , osteoclast , mapk/erk pathway , chemistry , cathepsin k , osteolysis , cancer research , pharmacology , microbiology and biotechnology , medicine , phosphorylation , biochemistry , biology , dentistry , receptor , chromatography , activator (genetics)
Osteolytic bone diseases including osteoporosis are commonly accompanied with enhanced osteoclast formation and bone resorption. Naringin, a natural occurring flavonoid has been found to protect against retinoic acid‐induced osteoporosis and improve bone quality in rats. Here, we showed that naringin perturbs osteoclast formation and bone resorption by inhibiting RANK‐mediated NF‐κB and ERK signaling. Naringin suppressed gene expression of key osteoclast marker genes. Naringin was found to inhibit RANKL‐induced activation of NF‐κB by suppressing RANKL‐mediated IκB‐α degradation. In addition, naringin inhibited RANKL‐induced phosphorylation of ERK. This study identifies naringin as an inhibitor for osteoclast formation and bone resorption, and provides evidence that natural compounds such as naringin might be beneficial as an alternative medicine for the prevention and treatment of osteolysis.